http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-732983-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22bcb0efb17af5d7eb47a6365dad2333 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2230-201 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2230-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-3334 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-1723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-16827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-1452 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-1408 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-148 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-142 |
| filingDate | 2015-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08b1dcdbbaad21d6d33a566f29e01b48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690b102a8d2fd00939cab0a2ce9ef282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_750efe6f3b94b8bff360a9f42948ac3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3e44ed801e4b190a5b85ef6f62e6f2b |
| publicationDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-732983-A |
| titleOfInvention | Infusion system with concurrent tpn/insulin infusion |
| abstract | In present practice, TPN solution administration is reduced from the required dosing for the patient to minimize hyperglycemia and avoid glucose shock. Insulin is premixed in the same IV bag or container with the TPN solution based on calculated requirements for the patient, adding to clinician time and risk of error. Insulin dosing also requires modulation based on monitored glucose levels during infusion. Subcutaneous insulin infusions can be administered to compensate for advancing hyperglycemia, but for hypoglycemic situations increased TPN (and specifically dextrose) delivery is indicated. Thus, infusion of both TPN and insulin as presently practiced is complex and time consuming. Accordingly, an infusion system to provide concurrent TPN/insulin infusion is provided to address the above disadvantages, including: a fluid administration set having a primary line in fluid communication with the TPN source, a secondary line in fluid communication with the insulin source, and a common outlet line; a pump operable to removably receive the fluid administration set, the pump being operable to concurrently move the TPN solution through the primary line in response to a TPN solution flow rate signal and the insulin solution through the secondary line in response to an insulin solution flow rate signal; and a flow controller operable to provide the TPN solution flow rate signal and the insulin solution flow rate signal to the pump. The flow controller is further operable to vary the TPN solution flow rate signal and the insulin solution flow rate signal to vary a ratio of TPN solution to insulin solution provided to the common outlet line. |
| priorityDate | 2014-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 108.